Differential expression of apoptomiRs in myeloproliferative neoplasms

Nunes, Natália S.; Tognon, Raquel; Moura, Lívia Gonzaga; Kashima, Simone; Covas, Dimas Tadeu; Santana, Mary Elizabeth de; Souto, Elizabeth Xisto; Zanichelli, Maria Aparecida; Simões, Belinda Pinto; Souza, Ana Maria de; Castro, Fabíola Attié de

doi:10.3109/10428194.2013.767453

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The haematopoietic system is subject to a high cellular turnover rate, which makes it particularly sensitive to disturbance in the apoptosis process (28). Altered control of pro-and anti-apoptotic genes and in the relation with JAK2 or STAT5 signaling routes, seem to lead to myeloaccumulation and myeloproliferation, participating in the pathogenesis of MPNs (19,(29)(30)(31)(32)(33)(34)(35).…”

Section: Introductionmentioning

confidence: 99%

Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea

et al. 2018

View full text Add to dashboard Cite

Several single nucleotide polymorphisms (SNPs) influencing DNA repair capacity and apoptotic status may confer genetic predisposition to Philadelphia-chromosome negative myeloproliferative neoplasms (PN-MPNs), and influence therapeutic response and the clinical course. In the present study, whether SNPs in genes involved in apoptosis and the base excision repair (BER) pathway was evaluated. In addition, some known risk factors in PN-MPNs that may influence survival and therapeutic response to hydroxyurea (HU) were analyzed, taking into account three items: Disease progression, predisposition to new non-myeloid neoplasms and thrombotic events. The present study involved a total of 133 Caucasian Portuguese PN-MPNs patients treated with HU, whereby 17 cases showed progression to myelofibrosis/leukemia, 11 developed new non-myeloid neoplasms and 22 presented with thrombotic events. Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)= 0.24; 95% confidence interval (CI), 0.08-0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98-13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13-112.28], APEX1 Asp148Glu [OR= 0.28; 95% CI, 0.74-1.03], and XRCC1 Arg194Trp [OR= 6.60; 95% CI, 1.60-27.06]}. Moreover, globally caspase and BER polymorphisms influenced the development of new nonmyeloid malignancies [CASP8 Asp270His (OR=5.90; 95% CI, 1.42-24.62) and XRCC1 Arg399Gln (OR=0.27; 95% CI, 0.07-1.03)]. On the other hand, only the BER pathway had a role in the presence of thrombotic events [XRCC1 Gln399Arg (OR= 0.35; 95% CI, 0.14-0.88)].JAK2 mutation had no influence on these complications. Larger studies are required to confirm these results, and to provide conclusive evidence of association between these and other variants with PN-MPNs therapeutic response and clinical evolution. However, this study may allow the development of drugs more directly targeted to the pathophysiology of the disease, with high efficacy, fewer adverse effects, contributing to compliance of patients with treatments. The clinical indication for classical drugs, including HU, may be guided by variant genes, which may provide additional beneficial effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Our research team has reported on the deregulated expression of genes of the extrinsic apoptosis pathway and BCL-2 family members in PV, ET and PMF patients' hematopoietic stem cells and leukocytes [5][6][7]. These findings are associated with mononuclear cell resistance to apoptosis induced by different drugs in vitro and deregulation of microRNAs that target apoptosis-related genes [5,8]. MPN patients display increased expression of the anti-apoptotic molecules pERK and pAKT and deregulated expression of BCL-2 family members and FLIP, an inhibitor of the extrinsic apoptosis pathway [5][6][7][9][10][11].…”

mentioning

confidence: 90%

Apoptosis- and cell cycle-related genes methylation profile in myeloproliferative neoplasms

Tognon

Nunes

Ambrósio

et al. 2015

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

“…de suprimir e controlar a resposta imune exacerbada, podendo inibir a proliferação de diversos tipos de células imunes, induzir a proliferação de linfócitos T e B regulatórios, e favorecer a maturação de células dendríticas (BERNARDO;FIBBE, 2013;JONES et al, 2007;CHO, 2013;NAUTA et al, 2006;TYNDALL;GRATWOHL, 2009 CHEN et al, 2008;MEIRELLES et al, 2009;ORLIC et al, 2003;SINGER;CAPLAN, 2011 STENVANG et al, 2012;NUNES;CASTRO, 2013), atuando como programadores da morte celular, orquestrados pela família de proteínas BCL-2 e proteínas IAPs (DEJEAN et al, 2010). Pertubações na expressão de miRNAs estão fortemente associadas com a patogênese de diversas neoplasias humanas (VECCHIONE; CROCE, 2010).…”

Section: Mutações Iniciadoras (Driver) E Marcadores Clonaisunclassified

Células estromais mesenquimais multipotentes em neoplasias mieloproliferativas: caracterização fenotípica, molecular e funcional

Cominal¹

View full text Add to dashboard Cite

Differential expression of apoptomiRs in myeloproliferative neoplasms

Cited by 5 publications

References 15 publications

Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea

Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea

Apoptosis- and cell cycle-related genes methylation profile in myeloproliferative neoplasms

Células estromais mesenquimais multipotentes em neoplasias mieloproliferativas: caracterização fenotípica, molecular e funcional

Contact Info

Product

Resources

About